Drug Interaction Report
3 potential interactions and/or warnings found for the following 2 drugs:
- cytarabine liposomal / daunorubicin liposomal
- vadadustat
Interactions between your drugs
DAUNOrubicin liposomal cytarabine liposomal
Applies to: cytarabine liposomal / daunorubicin liposomal, cytarabine liposomal / daunorubicin liposomal
Using DAUNOrubicin liposomal together with cytarabine liposomal or other chemotherapy drugs may increase the risk of side effects, especially those that affect the bone marrow or gastrointestinal tract. You may experience a greater number or more severe side effects such as nausea; vomiting; diarrhea; loss of appetite; mouth sores; abdominal pain; delayed wound healing; and impaired bone marrow function resulting in low numbers of different types of blood cells. You may also be more likely to develop anemia, bleeding problems, or infections due to low blood cell counts. You should seek medical attention if you develop paleness, fatigue, dizziness, fainting, unusual bruising or bleeding, fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. You may need a dose adjustment or more frequent monitoring by your doctor to safely use these medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
DAUNOrubicin liposomal vadadustat
Applies to: cytarabine liposomal / daunorubicin liposomal, vadadustat
Consumer information for this interaction is not currently available.
MONITOR: Coadministration with vadadustat, an inhibitor of breast cancer resistance protein (BCRP), may increase the plasma concentrations and pharmacologic effects of BCRP substrates. The proposed mechanism involves decreased clearance due to inhibition of BCRP by vadadustat. According to product labeling, when vadadustat was coadministered with the BCRP substrates sulfasalazine, simvastatin and rosuvastatin, systemic exposure (AUC) of the substrates increased 4.5-fold, 2-fold, and 2 to 3-fold, respectively. However, no substantial change in exposure to sulfasalazine's active metabolite was observed.
MANAGEMENT: Caution is advised when vadadustat is used concomitantly with drugs that are substrates of the breast cancer resistance protein (BCRP) transporter. Monitoring for signs and symptoms of increased exposure to the BCRP substrate should be considered whenever vadadustat is added to or withdrawn from therapy. The prescribing information for concomitant medications may be consulted to assess the benefits versus risks of coadministration, as well as any dosage adjustments that may be required during coadministration and/or following the discontinuation of a BCRP inhibitor.
Drug and food interactions
vadadustat food
Applies to: vadadustat
Consumer information for this interaction is not currently available.
MONITOR: Smoking and alcohol consumption during therapy with vadadustat may increase the risk of gastrointestinal erosions. Serious erosions, including gastrointestinal bleeding and the need for red blood cell transfusions, have been reported during vadadustat clinical trials. Patients with a history of gastrointestinal erosion, peptic ulcer disease, and current tobacco smokers and alcohol drinkers may be at higher risk of gastrointestinal injury.
MANAGEMENT: Caution is advised if vadadustat is prescribed to current tobacco smokers or alcohol drinkers. Patients should be advised to contact their physician if they develop potential signs and symptoms of gastrointestinal injury such as abdominal pain, hematemesis, trouble swallowing, chest or throat pain, and/or black, tarry stools.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Venclexta
Venclexta may be used to treat chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma ...
Vidaza
Vidaza is used to treat certain types of bone marrow cancers and blood cell disorders. Learn about ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Tibsovo
Tibsovo (ivosidenib) is a once-daily oral medication that targets a specific gene mutation called ...
Xospata
Xospata (gilteritinib) is used to treat acute myeloid leukemia (AML) with a FLT3 mutation. Xospata ...
Revuforj
Revuforj is used to treat acute leukemia with a lysine methyltransferase 2A gene translocation ...
Vanflyta
Vanflyta (quizartinib) is an oral targeted treatment called a kinase inhibitor that may be used to ...
Idhifa
Idhifa (enasidenib) is used to treat acute myeloid leukemia in adults who have a mutation in the ...
Onureg
Onureg (azacitidine) is used for the continued treatment of adult patients with acute myeloid ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.